P
Pauline Brice
Researcher at University of Paris
Publications - 243
Citations - 14207
Pauline Brice is an academic researcher from University of Paris. The author has contributed to research in topics: Brentuximab vedotin & Follicular lymphoma. The author has an hindex of 56, co-authored 227 publications receiving 12729 citations.
Papers
More filters
Journal ArticleDOI
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma
Franck Morschhauser,Nathan Fowler,Pierre Feugier,Reda Bouabdallah,Hervé Tilly,M Palomba,Christophe Fruchart,Edward N. Libby,Rene-Olivier Casasnovas,Ian W. Flinn,Corinne Haioun,Hervé Maisonneuve,Loic Ysebaert,Nancy L. Bartlett,Kamal Bouabdallah,Pauline Brice,Vincent Ribrag,Nicolas Daguindau,Steven Le Gouill,Gian Matteo Pica,Alejandro Martin Garcia-Sancho,Armando Lopez-Guillermo,Jean-François Larouche,Kiyoshi Ando,Maria Gomes da Silva,M. Andre,Pierre Zachee,Laurie Sehn,Kensei Tobinai,Guillaume Cartron,David Liu,Jianming Wang,Luc Xerri,Gilles Salles +33 more
TL;DR: Among patients with previously untreated follicular lymphoma, efficacy results were similar with rituximab plus lenalidomide and ritudinab plus chemotherapy (with both regimens followed by ritukimab maintenance therapy).
Journal ArticleDOI
CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.
Richard Delarue,Corinne Haioun,Vincent Ribrag,Pauline Brice,Alain Delmer,Hervé Tilly,Gilles Salles,Achiel Van Hoof,Olivier Casasnovas,Nicole Brousse,François Lefrère,Olivier Hermine +11 more
TL;DR: It is confirmed that induction with rituximab and cytarabine-based regimens is safe and effective in MCL patients and compared with R-CHOP(21) induction in a multicentric European protocol.
Journal ArticleDOI
A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
Andres Forero-Torres,John P. Leonard,Anas Younes,Joseph D. Rosenblatt,Pauline Brice,Nancy L. Bartlett,André Bosly,Lauren Pinter-Brown,Dana A. Kennedy,Eric L. Sievers,Ajay K. Gopal +10 more
TL;DR: It is demonstrated that weekly administration of SGN‐30 is safe, with modest clinical activity in patients with ALCL, and no specific pattern of adverse events was observed in either disease group.
Journal ArticleDOI
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Catherine Sebban,Nicolas Mounier,Nicole Brousse,Coralie Belanger,Pauline Brice,Corinne Haioun,Hervé Tilly,Pierre Feugier,Reclah Bouabdallah,Chantal Doyen,Gilles Salles,Bertrand Coiffier +11 more
TL;DR: After long-term follow-up, the study showed that there was no statistically significant benefit in favor of first-line high-dose therapy in patients with follicular lymphoma and high- dose therapy should be reserved for relapsing patients.
Journal ArticleDOI
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Robert T. Chen,Pier Luigi Zinzani,Hun Ju Lee,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Jianxin Lin,Eunhee Kim,Akash Nahar,Arun Balakumaran,Craig H. Moskowitz +17 more
TL;DR: Results confirmed the effective antitumor activity, durability of response, and manageable safety of pembrolizumab monotherapy in RRcHL, regardless of prior treatment and including chemoresistant cHL.